Which AI Accelerator Stock Has Dominated in 2026: Broadcom or Marvell?

Marvell Technology is up 218% YTD versus Broadcom’s 10%, driven by accelerating AI-related demand and raised FY2027/FY2028 revenue outlooks. Marvell reported Q1 FY2027 revenue of $2.418 billion (+28% YoY) and guided Q2 revenue to $2.7 billion, while Broadcom posted $22.19 billion in Q2 FY2026 revenue with AI semiconductor revenue of $10.8 billion (+143% YoY) and Q3 AI guidance of $16 billion. The article is constructive on both names, but emphasizes that Marvell’s smaller, more pure-play AI exposure has delivered the bigger stock re-rating.

Analysis

The market is rewarding purity and optionality more than absolute earnings power. MRVL’s move is a classic multiple-expansion trade on a narrower AI revenue mix, where each incremental design win changes the earnings trajectory enough to justify a higher equity beta; AVGO’s much larger AI dollars are mechanically less visible because they are being absorbed into a multi-engine conglomerate. Second-order, this means suppliers and adjacent beneficiaries tied to custom accelerators, optics, and rack-scale interconnect may continue to outperform even if broad semiconductor beta cools.

The main near-term risk is not demand rollover but expectation compression. MRVL now looks like a company trading on an accelerating cadence that must be repeatedly validated every quarter; any guide that merely meets, rather than beats, the implied ramp risks a sharp de-rating because the stock is already discounting a clean multi-year run-rate inflection. AVGO’s risk profile is the opposite: less air underneath the stock, but also less upside unless the AI contribution proves large enough to move consolidated growth and margin mix more materially than the street expects.

Consensus appears to underappreciate how quickly positioning can reverse in high-beta AI winners. Retail sentiment and momentum funds can amplify both names, but MRVL is more vulnerable to a 10-15% drawdown on a single guide-down or delayed deployment cycle, while AVGO’s cleaner capital-return profile and lower beta make it a better relative hedge if the AI trade de-risks. The contrarian angle is that AVGO may actually be the better risk-adjusted way to express the same AI thesis over 6-12 months, especially if investors rotate from story stock to cash-flow compounding.

Key Decisions for Investors

• Rotate from outright MRVL exposure into an MRVL/AVGO pair trade: long AVGO, short MRVL, sized for equal dollar AI-exposure rather than equal market cap; thesis is that MRVL’s multiple is more vulnerable to any execution blemish over the next 1-2 earnings cycles.
• If long MRVL, hedge with short-dated put spreads into the next earnings/guidance event (30-60 DTE); risk/reward is asymmetric because the stock is priced for continued acceleration, so a merely in-line print could compress 15-20% of upside in a day.
• Use AVGO as the core AI infrastructure long for a 6-12 month horizon; its cash return, lower beta, and diversified earnings base should outperform if AI spending broadens but stops rewarding pure-play optionality.
• Buy MRVL on a post-earnings pullback only if guide remains structurally upward; entry should be after volatility resets, since chasing strength here offers poor payoff versus the downside from any quarter-to-quarter deceleration.
• For tactical upside, prefer AVGO call spreads over outright stock if looking for AI upside without full-duration valuation risk; this limits downside while preserving participation if the market re-rates AI infrastructure breadth.